King-Friend subsidiary gets FDA nod for adenosine production

Nanjing King-Friend Biochemical Pharmaceutical (SSE:603707) announced that its subsidiary, Meitheal Pharmaceuticals, Inc., has received FDA approval to add King-Friend's Nanjing facility as an approved manufacturing site for Adenosine Injection, 3mg/mL (60 mg/20 mL, 90 mg/30 mL), under ANDA number 077425. The product, indicated for patients unable to undergo sufficient exercise during thallium-201 myocardial perfusion imaging, will soon be launched in the United States. While this approval is expected to positively impact the company's operating results, King-Friend cautions investors about potential risks related to market conditions and uncertainties that could affect sales performance. The company has invested approximately CNY 252.65 million in the research and development of adenosine injections.